Note: Descriptions are shown in the official language in which they were submitted.
CA 02610773 2007-12-05
1
DESCRIPTION
CLARITHROMYCIN OR A SALT THEREOF FOR USE IN THE TREATMENT OR
PREVENTION OF PULMONARY DISEASE INDUCED BY DESTRUCTION OF
PULMONARY ALVEOLI
Technical Field
[0001] This invention relates to the use of
clarithromycin or a salt thereof for the treatment or
prevention of pulmonary disorders caused by the destruction
of pulmonary alveoli. More particularly, it relates to a
therapeutic or prophylactic agent comprising as an effective
ingredient, clarithromycin or a salt thereof, a
pharmaceutical composition comprising clarithromycin or a
salt thereof, and a method of administering clarithromycin
or a salt thereof to a mammal, for the purpose of such
treatment or prevention, as well as to the use of
clarithromycin or a salt thereof in the manufacture of a
medicament.
Background Art
[0002] The lung branches out from bronchi and is
gradually subdivided finely to form the eventual baggy
structures which are referred to as "alveoli (or alveolus)".
The alveolus is composed of alveolar epithelial cells,
vascular cells, and extracellular matrices (such as elastin
or collagen). The alveolus is an important site where gas
exchange in the body is conducted.
CA 02610773 2007-12-05
2
[0003] Pulmonary emphysema is a symptom where the
alveolar walls are destroyed and the microstructures of the
alveoli are hollowed out. Pulmonary emphysema reduces gas
exchange efficiency and the elastic recoil of the whole lung,
and it eventually lowers pulmonary functions.
[0004] It was known that inflammatory cells, such as
alveolar macrophages or neutrophiles recruited into the lung,
were strongly implicated in pulmonary emphysema which were
activated by smoking, air pollution, noxious gas or the like
(Barnes, P.J. et al., Nature Reviews/Drug Discovery, Vol. 1,
437-446 (2002)). It was reported that the macrophages and
neutrophiles were activated by harmful substances in tobacco
smoke or polluted air (although the detailed mechanism is
unknown) and released substances (such as cytokines or
proteases) capable of enhancing inflammation to take part in
the destruction of the alveolar walls (Barnes, P.J. et al.,
Pharmacol Rev. 2004 Dec; 56(4):515-48).
[0005] At present, bronchodilators which improve the
restriction of airflow, such as anticholinergic agents and
/32 receptor stimulants, are widely used as therapeutic
agents for pulmonary emphysema. However, they have not been
able to alleviate the destruction of pulmonary alveoli and
to retard the progression of the pulmonary emphysema itself.
The use of anti-inflammatory agents represented by steroids
is recommended in the acute exacerbation stage of chronic
obstructive pulmonary diseases (COPD), i.e., cases involving
infection and deterioration of pulmonary functions. It has,
CA 02610773 2007-12-05
3
however, been reported that they are ineffective against the
pulmonary emphysema itself. As pertinent art, azithromycins
having a 15-membered ring were reported to display
effectiveness against non-infectious inflammatory diseases
(Japanese Published Application 2004-531539; JPA2004531539
or W02002/087596). However, it was also pointed out that
14-membered macrolides differ from 15-membered macrolides
with respect to pharmacological actions including anti-
inflammatory action (ibid.).
Disclosure of Invention
Problems to Be Solved
[0006] It is an object of this invention to provide a
therapeutic or prophylactic agent for a pulmonary disorder
caused by the destruction of pulmonary alveoli.
Means for Solving the Problems
[0007] As a result of intensive and diligent research,
the present inventors have accomplished this invention upon
finding that clarithromycin reduces inflammatory reaction to
improve a pulmonary emphysema condition in model mice with
tobacco-smoke induced pulmonary emphysema mimicking human
pulmonary emphysema and that clarithromycin is useful as a
therapeutic or prophylactic agent for a pulmonary disease
(particularly, pulmonary emphysema).
[0008] Specifically, this invention provides a method for
treating or preventing a pulmonary disorder caused by the
destruction of pulmonary alveoli in a mammal (principally,
in human) in need of such treatment or prevention, the
CA 02610773 2007-12-05
4
method comprising administering to the mammal, an effective
amount of clarithromycin or a salt thereof.
[0009] This invention also provides a pharmaceutical
composition for the treatment or prevention of a pulmonary
disorder caused by the destruction of pulmonary alveoli
comprising an effective amount of clarithromycin or a salt
thereof and a pharmaceutically acceptable carrier.
[0010] Further, this invention provides a therapeutic or
prophylactic agent for a pulmonary disorder caused by the
destruction of pulmonary alveoli comprising as an effective
ingredient, clarithromycin or a salt thereof.
[0011] In addition, this invention provides the use of
clarithromycin or a salt thereof in the manufacture of a
medicament for the treatment or prevention of a pulmonary
disorder caused by the destruction of pulmonary alveoli.
[0012] In the method of treatment/prevention and the
therapeutic/prophylactic pharmaceutical composition
mentioned above, the efficacy of clarithromycin or a salt
thereof is excellent where the pulmonary disorder is
pulmonary emphysema or a pulmonary emphysema condition.
[0013] In the method of treatment/prevention and the
therapeutic/prophylactic pharmaceutical composition
mentioned above, the efficacy of clarithromycin or a salt
thereof is especially excellent where the pulmonary
emphysema condition is chronic obstructive pulmonary disease.
[0014] This invention also provides an in vivo method for
reducing the cell counts of macrophages and/or neutrophiles
CA 02610773 2007-12-05
in an mammal, the method comprising administering to the
mammal, clarithromycin or a salt thereof in an amount
sufficient to reduce the cell counts.
Effects of the Invention
5 [0015] According to this invention, it has been
demonstrated that clarithromycin or a salt thereof is
effective as a therapeutic or prophylactic agent for a
pulmonary disorder caused by the destruction of pulmonary
alveoli.
Best Mode for Carrying Out the Invention
[0016] As used in the present specification, the term
"pulmonary disorder caused by the destruction of pulmonary
alveoli" refers to a pulmonary disease triggered by the
destruction of the cells of pulmonary alveoli due to smoking,
air pollution, noxious gas, aging or the like. Especially,
of note is "pulmonary emphysema (condition)" by which owing
to the destruction of pulmonary alveoli, the pulmonary
alveor wall disintegrates to cause the adhesion of adjoining
pulmonary alveoli and to form a cavity. In the pulmonary
emphysema condition, the pulmonary alveoli of the peripheral
respiratory tract are further destroyed, resulting in the
obstructive disorder of airflow. This symptom is classified
into "chronic obstructive pulmonary disease." The diseases
displaying symptoms that are characterized by the
aforementioned pulmonary alveoli destruction are
collectively referred to as "pulmonary disorder caused by
CA 02610773 2012-11-06
6
the destruction of pulmonary alveoli." These pulmonary
disorders may often be accompanied by infections.
[0017] Clarithromycin used in this invention is a known
compound; and its detailed description (production method,
antibacterial activity, etc.) is disclosed in, for example,
Japanese Published Patent Application Sho 61-52839
(JP61052839B).
As
used herein, the term "a salt of clarithromycin" refers to a
pharmaceutically acceptable salt of clarithromycin.
Specifically, there are mentioned the salts with organic
acids such as tartaric acid, citric acid, stearic acid, and
succinic acid; the salt with methanesulfonic acid; the salt
with aminoethanesulfonic acid; and the salts with amino
acids such as aspartic acid and glutamic acid. In place of
clarithromycin a pharmaceutically acceptable derivative
thereof may be used in this invention. This derivative
refers to one that bears the basic skeleton of
clarithromycin which has been derivatized and that displays
the same pharmacological function as does clarithromycin.
The particularly useful derivative is an ester of
clarithromycin that experiences hydrolysis in vivo to
release clarithromycin. These derivatives are also referred
to as "prodrug(s)" and particular esters are well known to
one skilled in the art.
[0018] When clarithromycin is used in this invention, it
may be formulated into standard pharmaceutical preparations.
CA 02610773 2007-12-05
7
Specifically, clarithromycin or a salt thereof is compounded
with a pharmaceutically acceptable carrier (e.g., an
excipient, binder, disintegrating agent, flavoring agent,
emulsifier, diluent, and solublizer) to prepare a
pharmaceutical composition. This pharmaceutical composition
may be administered to a mammal in the form of a preparation
that is suitable for an oral or parenteral route, including
tablets, pills, powders, granules, capsules, solutions,
emulsions, suspensions, injectables, suppositories,
inhalants and transdermals.
[0019] In producing these preparations, there may be
added a solvent, a solublizer, an isotonicating agent, a
preservative, an antioxidant, an excipient, a binder, a
lubricant, and a stabilizer.
[0020] Specifically, the solvents include water,
physiological saline, etc.; the solublizers include ethanol,
polysorbates, cremophor, etc.; the excipients include
lactose, starch, crystalline cellulose, mannitol, maltose,
calcium hydrogenphosphate, light anhydrous silicic anhydride,
calcium carbonate, etc.; the binders include starch,
polyvinylpyrrolidone, hydroxypropyl cellulose, ethyl
cellulose, carboxymethylcellulose, gum arabic, etc.; the
disintegrating agents include starch, calcium
carboxymethylcellulose, etc.; the lubricants include
magnesium stearate, talc, hydrogenated oils, etc.; and the
stabilizers include lactose, mannitol, maltose, polysorbates,
macrogols, polyoxyethylene hydrogenated castor oil, etc.
CA 02610773 2007-12-05
8
[0021] To the preparations, there may be added glycerol,
dimethylacetamide, 70% sodium lactate, a surfactant, and a
basic substance (e.g., sodium hydroxide, ethylenediamine,
ethanolamine, sodium carbonate, arginine, meglumine, and
Tris-aminomethane) where necessary.
[0022] As used herein, the term "effective amount" means
an amount or an amount of composition sufficient to exert a
desired pharmacological effect when clarithromycin or a salt
thereof, preferably as a pharmaceutical composition, is
administered to a mammal in need of treatment or prevention.
When clarithromycin or a salt thereof is to be used for the
treatment purpose, the desired pharmacological effect means
that the cure or alleviation of the symptom can be achieved
in the mammal showing the developed symptom. When
clarithromycin or a salt thereof is to be used for the
prevention purpose, the desired pharmacological effect means
the inhibition of the crisis in a mammal. In this case,
preventive administration is conducted to the mammal
suspected of potential crisis or having high risk of crisis
prior to such crisis.
[0023] The dosage of clarithromycin or a salt thereof
will be determined in consideration of the animal test
results and other various circumstances so that the full
dose may not exceed a certain level when it is administered
singly or repeatedly. Needless to indicate, the actual
dosage will vary depending on the method of administration
and the conditions of the patient or the animal to be
CA 02610773 2007-12-05
9
treated, specifically, within the range of from 10 to 1000
mg and on the age, the body weight, the gender, the
susceptibility, the diet (feed), the administration time,
any drug used together, or the degree of the symptom. The
suitable dosage and the frequency of administration need to
be determined by the medical specialist after optimum dose
determination according to the aforementioned guideline.
Examples
[0024] This invention will be concretely described
further by referring to a preparation example and test
examples; however, the invention should not be limited to
those examples.
Preparation Example 1
clarithromycin 50 mg
lactose 40 mg
corn starch 49.75 mg
crystalline cellulose 17 mg
carmellose calcium 17 mg
hydroxypropyl cellulose 5.25 mg
magnesium stearate 1 mg
total 180 mg
[0025] Clarithromycin, lactose, corn starch, crystalline
cellulose, and carmellose calcium were uniformly mixed. To
this was added a 10% hydroxypropyl cellulose aqueous
solution. After blending the mixture, the granules were
dried and sieved with a 30M-screen to make uniform granules.
CA 02610773 2007-12-05
Magnesium stearate was added to the granules and it was
compressed to form tablets.
[0026] The pharmacological action of clarithromycin
(improvement to a pulmonary emphysema condition) will be
5 next explained by way of test examples.
[0027] Test Example 1: Pharmacological effect in model
mice with tobacco smoke-induced pulmonary emphysema
The model mice with tobacco smoke-induced
pulmonary emphysema mimicking human pulmonary emphysema were
10 constructed according to the method as described in
Hautamaki, R.D. et al., Science 1997, 277:2002-2004 or
Shapiro, S.D. et al., Am. J. Pathol (2003) 163:2329-2335.
Specifically, C57black/6 female mice of 12-weeks old were
exposed to tobacco smoke at two cigarettes per day, 6 days
per week for 6 months.
[0028] Administration of clarithromycin was carried out
orally at the rate of 25, 50 or 100 mg/body weight twice
daily (morning and evening) during the tobacco smoke
exposure period. The plasma AUC0¨ of clarithromycin
obtained when 50 mg/kg was singly administered to the mice
was 2.677 gg.hr/m1 while the plasma AUCO¨ of clarithromycin
obtained when 200 mg of clarithromycin was singly
administered to a normal human subject was 8.98gg.hr/ml.
The former concentration was substantially lower than the
latter one and was an adequate concentration to be used
clinically.
CA 02610773 2007-12-05
11
[0029] The index of the improvement to the pulmonary
emphysema condition followed the method as described in
Hautamaki, R.D. et al., ibid. or Shapiro, S.D. et al., ibid.
[0030] Hematoxylin eosin-stained pathological specimens
were prepared from the model mice and ten visual fields
under a microscope were randomly selected, where the average
sizes of pulmonary alveoli were measured. An increase in
the average size of pulmonary alveolus is considered as an
index of the destruction of pulmonary alveoli, i.e., the
pulmonary emphysema condition.
[0031] Table 1 shows the improvement factor of pulmonary
emphysema in the model mice with tobacco smoke induced
pulmonary emphysema. Six months' smoking (i.e., exposure to
tobacco smoke) increased the pulmonary emphysema rate by 20%
relative to the non-smoking group (control). The pulmonary
emphysema was improved by 47% in the group administered with
clarithromycin (25 mg/kg) and by a maximum of up to 87% in
the group administered with clarithromycin (50 mg/kg).
These results indicate that clarithromycin is effective
against pulmonary emphysema (or pulmonary emphysema
condition).
[0032]
CA 02610773 2007-12-05
12
Table 1
pulmonary statistical pulmonary improvement
alveolus size significance emphysema factor (%)
(gm) rate (%)
non-smoking 32.21+0.507 0
smoking + 38.51d-0.765 0.0004 (vs. 20 0
solvent non-smoking)
smoking + 35.60+1.425 0.1001 (vs. 10.6 47
CAM(25 mg/kg) smoking)
smoking + 33.16+0.890 0.0046 (vs. 3 85
CAM(50 mg/kg) smoking)
smoking + 34.35+0.936 0.0092 (vs. 6.7 66.5
CAM(100 mg/kg) smoking)
(mean SE)
[0033] The cell counts of inflammatory cells (macrophages
and neutrophiles) in the bronchoalveolar lavage fluids after
six months' exposure were measured to provide an index of
the inflammatory condition in the model mice with tobacco
smoke-induced pulmonary emphysema. The results are shown in
Fig. lA and Fig. 1B.
[0034] The cell counts of macrophages and neutrophiles
increased as the pulmonary emphysema progressed. These
cells produce the proteases that are involved in pulmonary
emphysema. These cell increases exacerbate the pulmonary
emphysema. Administration of clarithromycin reduced the
cell counts of macrophages and neutrophiles in a dose-
dependant manner. This result indicates that clarithromycin
inhibits inflammation reaction and suppresses the
progression of pulmonary alveoli destruction.
[0035] It has been reported that as pulmonary emphysema
progresses, pulmonary functions deteriorate. It has also
been known that the pulmonary compliance, which is an index
of pulmonary functions, increases in model mice with tobacco
CA 02610773 2007-12-05
13
smoke-induced pulmonary emphysema. Thus, the pulmonary
compliance was measured in the model mice with tobacco
smoke-induced pulmonary emphysema after six months' exposure.
The result is shown in Fig. 2.
[0036] As the pulmonary emphysema progressed, the
pulmonary compliance (the index of pulmonary functions) was
increasing in the model mice with tobacco smoke-induced
pulmonary emphysema; however, the pulmonary compliance
recovered upon the administration of clarithromycin. This
result was in accord with the improvement of the pulmonary
emphysema ratio as well as with the decrease in the number
of the inflammatory cells, and it indicates that the
clarithromycin administration is useful for the treatment of
pulmonary emphysema (or pulmonary emphysema condition).
Industrial Applicability
[0037] According to this invention, clarithromycin or a
salt thereof is effective as a therapeutic or prophylactic
agent for a pulmonary disorder caused by the destruction of
pulmonary alveoli.
Brief Description of the Drawings
[0038] Fig. lA and Fig. 1B show the cell counts of
inflammatory cells (macrophages and neutrophiles) in
bronchoalveolar lavage fluids from model mice with tobacco
smoke-induced pulmonary emphysema after six months' exposure.
Fig. lA shows the cell count of macrophages. Fig. 1B shows
the cell count of neutrophiles.
CA 02610773 2007-12-05
14
[0039] Fig. 2
shows the results of pulmonary compliance
measured in the model mice with tobacco smoke-induced
pulmonary emphysema after six months' exposure.
